Investigational Therapies1

30

TOTAL MOLECULES

Phase III: 7 molecules

Phase II: 9 molecules

Phase I: 30 molecules

Select platforms, tumor types and/or phases below to learn more.

Learn more about Genentech's investigational therapies. Click to expand.

Tumor types
Development platforms
Phases

The compounds and their uses mentioned on this website are investigational and have not been approved by the US Food and Drug Administration. Efficacy and safety have not been established. The information presented should not be construed as a recommendation for use. The relevance of findings in preclinical studies to humans is currently being evaluated.

Phase III

  • Hematology
  • Small Molecules

Ipatasertib
(AKT inhibitor)

(GDC-0068, RG7440)a

Find out more about how ipatasertib, an Akt inhibitor, is proposed to work.

  • Breast
  • Gastrointestinal
  • Genitourinary
  • Small Molecules
  • Hematology
  • Antibody Drug Conjugates

Atezolizumab
(anti-PDL1 MAb)

(RG7446)

 

  • Breast
  • Gastrointestinal
  • Genitourinary
  • Gynecologic
  • Head and Neck
  • Hematology
  • Melanoma
  • Solid Tumor
  • Monoclonal Antibodies

Bevacizumab

(anti-VEGF MAb)

 

  • Gastrointestinal
  • Monoclonal Antibodies

Entrectinib
(ROS1/TRK inhibitor)

(RXDX-101, RG6268)c

 

  • Lung
  • Small Molecules

Venetoclax
(BCL-2 inhibitor)

(ABT-199/GDC-0199, RG7601)d

 

  • Hematology
  • Small Molecules

Phase II

  • Hematology
  • Small Molecules

Ipatasertib
(AKT inhibitor)

(GDC-0068, RG7440)a

Find out more about how ipatasertib, an Akt inhibitor, is proposed to work.

  • Breast
  • Gastrointestinal
  • Genitourinary
  • Small Molecules
  • Hematology
  • Antibody Drug Conjugates

Atezolizumab
(anti-PDL1 MAb)

(RG7446)

 

  • Breast
  • Gastrointestinal
  • Genitourinary
  • Monoclonal Antibodies

Cobimetinib
(MEK inhibitor)

(RG7421)e

 

  • Breast
  • Gastrointestinal
  • Hematology
  • Solid Tumor
  • Small Molecules

Codrituzumab
(anti-glypican 3 MAb)

(GC33, RG7686)f

 

  • Gastrointestinal
  • Monoclonal Antibodies

Entrectinib

(ROS1/TRK inhibitor)

(RXDX-101, RG6268)c

 

  • Lung
  • Pan Tumor
  • Small Molecules

Tiragolumab
(anti-TIGIT MAb)

(MTIG7192A, RG6058)

 

  • Lung
  • Monoclonal Antibodies

Venetoclax
(BCL-2 inhibitor)

(ABT-199/GDC-0199, RG7601)d

 

  • Breast
  • Hematology
  • Small Molecules

Phase I

  • Solid Tumor
  • T-cell Bispecific Antibodies
  • Hematology
  • Small Molecules

Ipatasertib
(AKT inhibitor)

(GDC-0068, RG7440)a

Find out more about how ipatasertib, an Akt inhibitor, is proposed to work.

  • Breast
  • Gastrointestinal
  • Genitourinary
  • Small Molecules
  • Hematology
  • T-cell Bispecific Antibodies
  • Hematology
  • Antibody Drug Conjugates

Antibody-drug conjugate

(RG6109)

 

  • Hematology
  • Antibody Drug Conjugates

Antibody-drug conjugate

(RG6148)

 

  • Breast
  • Antibody Drug Conjugates

Atezolizumab
(anti-PDL1 MAb)

(RG7446)

 

  • Breast
  • Gastrointestinal
  • Genitourinary
  • Gynecologic
  • Head and Neck
  • Hematology
  • Melanoma
  • Monoclonal Antibodies

BET inhibitor

(TEN-010, RG6146)g

 

  • Breast
  • Gynecologic
  • Hematology
  • Solid Tumor
  • Small Molecules

Bevacizumab
(anti-VEGF MAb)

 

  • Gastrointestinal

Cergutuzumab amunaleukin
(CEA-IL2v)

(RG7813)

 

  • Solid Tumor
  • Monoclonal Antibodies

Cobimetinib
(MEK inhibitor)

(RG7421)e

 

  • Gastrointestinal
  • Genitourinary
  • Head and Neck
  • Hematology
  • Small Molecules

Codrituzumab
(anti-glypican 3 MAb)

(GC33, RG7686)f

 

  • Gastrointestinal
  • Monoclonal Antibodies

Entrectinib

(ROS1/TRK inhibitor)

(RXDX-101, RG6268)c

 

  • Lung
  • Pan Tumor
  • Solid Tumor
  • Small Molecules

FAP-4-1BBL FP

(RG7827)

 

  • Solid Tumor
  • Monoclonal Antibodies

FAP-IL2v FP

(RG7461)

 

  • Breast
  • Genitourinary
  • Head and Neck
  • Lung
  • Solid Tumor
  • Monoclonal Antibodies

Glypican-3/CD3 biMAb

(CHU)f

 

  • Solid Tumor
  • Monoclonal Antibodies

HER2/CD3-TDB

(RG6194)

 

  • Breast
  • Monoclonal Antibodies

Monoclonal antibody

(RG6123)

 

  • Solid Tumor
  • Monoclonal Antibodies

Monoclonal antibody

(RG6160)

 

  • Hematology
  • Monoclonal Antibodies

Pan-RAF inhibitor

(RG6185)

 

  • Solid Tumor
  • Small Molecules

Personalized cancer vaccine

(RG6180)h

 

  • Solid Tumor
  • Personalized Cancer Vaccines

PI3K inhibitor

(GDC-0077, RG6114)

 

  • Breast
  • Solid Tumor
  • Small Molecules

Raf/MEK dual inhibitor

(CHU)f

 

  • Solid Tumor
  • Small Molecules

Selective estrogen receptor degrader

(SERD [3])

(GDC-9545, RG6171)

 

  • Breast
  • Small Molecules

Selicrelumab
(CD40 MAb)

(RG7876)

 

  • Solid Tumor
  • Monoclonal Antibodies

Tiragolumab

(anti-TIGIT MAb)

(MTIG7192A, RG6058)

 

  • Solid Tumor
  • Monoclonal Antibodies

Vanucizumab
(ANG2/VEGF biMAb)

(RG7221)

 

  • Gynecologic
  • Solid Tumor
  • Monoclonal Antibodies

Venetoclax
(BCL-2 inhibitor)

(ABT-199/GDC-0199, RG7601)d

 

  • Hematology
  • Small Molecules

aDeveloped in collaboration with Array BioPharma. bDeveloped in collaboration with Seattle Genetics. cIgnyta Inc acquisition. dJoint project with AbbVie. eDeveloped in collaboration with Exelixis. fDeveloped in collaboration with Chugai. gTensha acquisition. hDeveloped in collaboration with BioNTech.

Reference

  1. Roche third-quarter results 2018 presentation. www.roche.com/dam/jcr:f9cad8fc-8655-4692-9a85-efbe1cf7a59b/en/irp181017.pdf. Accessed October 17, 2018.